Reid Ian R
Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.
Rheum Dis Clin North Am. 2006 Nov;32(4):691-702, vi. doi: 10.1016/j.rdc.2006.08.002.
Bisphosphonates are the most commonly used agents in the management of metabolic bones diseases. Despite their established therapeutic value, a number of points of uncertainty remain, particularly in connection with their optimal long-term use. It is likely that definitive clinical trial data will not become available to resolve these questions, so careful clinical observation and caution are needed in patients who require treatment over periods of more than 10 years.
双膦酸盐是治疗代谢性骨病最常用的药物。尽管其治疗价值已得到确立，但仍存在一些不确定点，尤其是在其最佳长期使用方面。解决这些问题的确定性临床试验数据可能无法获得，因此对于需要超过10年治疗的患者，需要仔细的临床观察并谨慎使用。
